Choi Dongho, Lee Hyo-Won, Hur Kyung-Yul, Kim Jae-Joon, Park Gyeong-Sin, Jang Si-Hyong, Song Young-Soo, Jang Ki-Seok, Paik Seung-Sam
Department of Pathology, College of Medicine, Hanyang University, Seoul, South Korea.
World J Gastroenterol. 2009 May 14;15(18):2258-64. doi: 10.3748/wjg.15.2258.
To verify that CD markers are available for detecting cancer stem cell populations and to evaluate their clinical significance in colon cancer.
Immunohistochemistry for CD133, CD24 and CD44 was performed on the tissue microarray of 523 colorectal adenocarcinomas. Medical records were reviewed and clinicopathological analysis was performed.
In colorectal adenocarcinoma, 128 of 523 cases (24.5%) were positive and 395 cases (75.5%) were negative for CD133 expression. Two hundred and sixty-four of 523 cases (50.5%) were positive and 259 cases (49.5%) were negative for CD24 expression. Five hundred and two of 523 cases (96%) were negative and 21 cases (4%) were positive for CD44 expression. Upon clinicopathological analysis, CD133 expression was present more in male patients (P = 0.002) and in advanced T stage cancer (P = 0.024). Correlation between CD24 expression and clinicopathological factors was seen in the degree of differentiation (P = 0.006). Correlation between CD44 expression and clinicopathological factors was seen in the tumor size (P = 0.001). Survival was not significantly related to CD133, CD24 and CD44 expression.
CD markers were related to invasiveness and differentiation of colorectal adenocarcinoma. However, CD expression was not closely related to survival.
验证CD标志物可用于检测癌症干细胞群体，并评估其在结肠癌中的临床意义。
对523例大肠腺癌组织芯片进行CD133、CD24和CD44免疫组化检测。查阅病历并进行临床病理分析。
在大肠腺癌中，523例中有128例（24.5%）CD133表达阳性，395例（75.5%）阴性。523例中有264例（50.5%）CD24表达阳性，259例（49.5%）阴性。523例中有502例（96%）CD44表达阴性，21例（4%）阳性。经临床病理分析，CD133表达在男性患者中更多见（P = 0.002），在晚期T分期癌症中更多见（P = 0.024）。CD24表达与临床病理因素之间的相关性在分化程度方面可见（P = 0.006）。CD44表达与临床病理因素之间的相关性在肿瘤大小方面可见（P = 0.001）。生存率与CD133、CD24和CD44表达无显著相关性。
CD标志物与大肠腺癌的侵袭性和分化有关。然而，CD表达与生存率无密切关系。
